The move, confirmed to Reuters by Director of affordable medicines in the department, Khadija Jamaloodien, comes after the British drugmaker on Saturday got the go-ahead to restart trials in the United Kingdom, prompting Brazil to follow suit. Tests remain on hold in the United States pending an investigation and the Serum Institute of India said it would restart its trials once it had permission from the Drugs Controller General of India. --Reuters--